Marshall Wace Adds $52M in Arcutis Biotherapeutics, Inc. ($ARQT)

Marshall Wace has significantly increased its stake in Arcutis Biotherapeutics, Inc. (NasdaqGS: ARQT). According to the latest Form 13F filing with the SEC, the fund boosted its holdings by 435%, adding 1,977,545 shares during the reporting period. This brings its total position to 2,431,778 shares, valued at approximately $61.7 million.

What Changed in Marshall Wace's Arcutis Biotherapeutics Position

Marshall Wace's move represents a substantial increase from its previous holding of 454,233 shares. The fund's decision to add nearly 2 million shares suggests a strong interest in the biotechnology company, which is now reflected in a total holding valued at $61.7 million.

Other Institutional Activity in Arcutis Biotherapeutics

Other institutional investors have also been active in Arcutis Biotherapeutics. Suvretta Capital Management, LLC increased its holdings by 363,000 shares, ending with 12,327,000 shares worth about $290.4 million. BlackRock, Inc. added 100,832 shares to hold a total of 9,200,411 shares valued at $216.8 million. Meanwhile, State Street Corp significantly boosted its position by 807,896 shares, bringing its total to 6,296,197 shares, valued at $148.3 million.

Arcutis Biotherapeutics Stock Snapshot

Shares of Arcutis Biotherapeutics (NasdaqGS: ARQT) are trading around $25.38. The company has a market cap of $3.21 billion and a forward P/E ratio of 22.21. Its stock has experienced a 52-week low of $13.06 and a high of $31.77. The 50-day moving average is $22.67, with a 200-day moving average of $23.89. The company maintains a current ratio of 2.68 and a quick ratio of 2.26, with a debt-to-equity ratio of 60.47.

Recent Earnings

Arcutis Biotherapeutics reported revenue of $415.6 million, with a revenue growth rate of 60.1%. Despite this growth, the company recorded a net margin of -0.57% and a return on equity of -1.43%. The next earnings report is scheduled for August 5, 2026.

Insider Buying and Selling at Arcutis Biotherapeutics, Inc.

On June 5, 2026, several insiders made stock purchases. Patrick Heron bought 16,667 shares, Amit Munshi also acquired 16,667 shares, and Halley Gilbert purchased 5,778 shares. Sue-Jean Lin, Keith Leonard, and Neha Krishnamohan each bought 5,778 shares. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on Arcutis Biotherapeutics. On March 2, 2026, Mizuho maintained a buy rating with a $35.00 price target. Guggenheim and TD Cowen also kept buy ratings with the same price target. The consensus among analysts is a strong buy, with a mean price target of $34.63 based on eight opinions.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on developing treatments for skin diseases. Its lead product, ZORYVE, is a topical cream for plaque psoriasis and atopic dermatitis. The company also works on treatments for seborrheic dermatitis and scalp psoriasis. Founded in 2016 and headquartered in Westlake Village, California, Arcutis is led by CEO Todd Watanabe and employs 354 people.

Bottom Line

Marshall Wace's substantial increase in its stake in Arcutis Biotherapeutics highlights its confidence in the company's potential. Investors often track such filings to gauge institutional sentiment, though it's important to remember that 13F filings reflect past positions and not necessarily current holdings.